NO20062723L - Ikke-tabletterte, tyggbare, induviduelt doserte administrasjonsformer - Google Patents

Ikke-tabletterte, tyggbare, induviduelt doserte administrasjonsformer

Info

Publication number
NO20062723L
NO20062723L NO20062723A NO20062723A NO20062723L NO 20062723 L NO20062723 L NO 20062723L NO 20062723 A NO20062723 A NO 20062723A NO 20062723 A NO20062723 A NO 20062723A NO 20062723 L NO20062723 L NO 20062723L
Authority
NO
Norway
Prior art keywords
tableted
composition
water
stabilizing agent
individually dosed
Prior art date
Application number
NO20062723A
Other languages
English (en)
Norwegian (no)
Inventor
Jose Luis Fabregas Vidal
Antoni Masso Carbonell
Nuria Garcia Gonzalez
Pere Guiro Coll
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062723(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of NO20062723L publication Critical patent/NO20062723L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20062723A 2003-11-10 2006-06-12 Ikke-tabletterte, tyggbare, induviduelt doserte administrasjonsformer NO20062723L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.
PCT/EP2004/012658 WO2005048974A2 (en) 2003-11-10 2004-11-09 Non-tabletted, chewable, individually dosed administration forms

Publications (1)

Publication Number Publication Date
NO20062723L true NO20062723L (no) 2006-06-12

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062723A NO20062723L (no) 2003-11-10 2006-06-12 Ikke-tabletterte, tyggbare, induviduelt doserte administrasjonsformer

Country Status (25)

Country Link
US (1) US20070134318A1 (pt)
EP (1) EP1682097B1 (pt)
JP (1) JP4879021B2 (pt)
KR (1) KR20060116821A (pt)
CN (1) CN1878542A (pt)
AR (1) AR048050A1 (pt)
AT (1) ATE492270T1 (pt)
AU (1) AU2004290517B2 (pt)
BR (1) BRPI0416215A (pt)
CA (1) CA2548615A1 (pt)
CO (1) CO5690531A2 (pt)
DE (1) DE602004030706D1 (pt)
EC (1) ECSP066553A (pt)
ES (2) ES2235626B1 (pt)
IL (1) IL175285A (pt)
MY (1) MY143793A (pt)
NO (1) NO20062723L (pt)
NZ (1) NZ546375A (pt)
PE (1) PE20050488A1 (pt)
RU (1) RU2369379C2 (pt)
TW (1) TW200526266A (pt)
UA (1) UA90253C2 (pt)
UY (1) UY28586A1 (pt)
WO (2) WO2005048975A1 (pt)
ZA (1) ZA200602416B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CN101686942B (zh) * 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010013242A1 (en) 2008-07-29 2010-02-04 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
NZ597319A (en) 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (en) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methods of treating depressive disorders
TW202245744A (zh) 2021-02-09 2022-12-01 加拿大商再諾製藥公司 治療失樂症之方法及用途
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
WO2005048975A1 (en) 2005-06-02
CN1878542A (zh) 2006-12-13
AR048050A1 (es) 2006-03-29
ATE492270T1 (de) 2011-01-15
ES2235626A1 (es) 2005-07-01
CO5690531A2 (es) 2006-10-31
IL175285A0 (en) 2006-09-05
ES2358332T3 (es) 2011-05-09
EP1682097A2 (en) 2006-07-26
JP2007510690A (ja) 2007-04-26
JP4879021B2 (ja) 2012-02-15
ES2235626B1 (es) 2006-11-01
UY28586A1 (es) 2005-05-31
ZA200602416B (en) 2009-06-24
WO2005048974A3 (en) 2006-02-23
DE602004030706D1 (de) 2011-02-03
RU2369379C2 (ru) 2009-10-10
MY143793A (en) 2011-07-15
TW200526266A (en) 2005-08-16
EP1682097B1 (en) 2010-12-22
ECSP066553A (es) 2006-12-20
US20070134318A1 (en) 2007-06-14
UA90253C2 (ru) 2010-04-26
KR20060116821A (ko) 2006-11-15
RU2006120087A (ru) 2007-12-27
AU2004290517A1 (en) 2005-06-02
BRPI0416215A (pt) 2006-12-26
WO2005048974A2 (en) 2005-06-02
PE20050488A1 (es) 2005-08-24
IL175285A (en) 2011-04-28
CA2548615A1 (en) 2005-06-02
AU2004290517B2 (en) 2010-05-27
NZ546375A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
UA90253C2 (ru) Нетаблетированные жевательные дозировочные формы для индивидуального введения
ES2575994T3 (es) Sistema y procedimiento para preparar, aplicar y retirar un revestimiento superior para gráficos despegables
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
ATE219659T1 (de) Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie
EA200101266A1 (ru) Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество
TR200102504T2 (tr) Jelatinsiz hızlı dağılan dozaj formları.
ES8101894A1 (es) Procedimiento de obtencion de una matriz polimerica de difu-sion
JP2007510690A5 (pt)
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
CA2514897A1 (en) Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
DE69710756D1 (de) Orale zeitversetzt schnell freisetzende formulierung sowie verfahren zu deren herstellung
BR0206441A (pt) Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica de liberação modificada, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula e uma formulação
NZ595852A (en) Stable pharmaceutical composition comprising ethyl eicosapentaenoate
DK1313510T3 (da) Injicerbar farmaceutisk sammensætning til systemisk administration af farmakologisk aktive aktivstoffer indeholdende middelkædede triglycerider
CA1169770A (en) Antimycotic agent, in the form of sticks, with a high release of active compound
JP2016522792A5 (pt)
CO4560593A1 (es) Adhesivos para corrugado que emplean fibra de tapioca
JP2010531684A5 (pt)
PE20010303A1 (es) Nueva preparacion y forma de presentacion que contiene un agente activo labil en medio acido que consiste en un inhibidor de la bomba de protones labil en medio acido
CO2025008260A2 (es) Formulaciones relacionadas con hongo chaga, compuestos químicos, composiciones y métodos de producción y uso de los mismos
FI821422A0 (fi) Foerfarande foer framstaellning av ett nytt farmaceutiskt preparat
FI935051A0 (fi) Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser
NO20024231L (no) Lipidb¶rer
CA2523734A1 (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
MX2007006775A (es) Composiciones estables de fenofibrato con esteres de acido graso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application